The remarkable ability of LSD1 inhibition to convert a tumor resistant to PD-1 blockade to a tumor responsive to PD-1 blockade provides a means to increase the efficacy of anti-PD-1 cancer therapy and potentially turn “cold” tumors “hot” (169). Here, KDM1A is linked to neoplasm.